

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet 1 of 3

**Complete if Known**

Application Number	
Filing Date	March 31, 2004
First Named Inventor	Arzubi, Blas
Art Unit	
Examiner Name	
Attorney Docket Number	88885

U. S. PATENT DOCUMENTS

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number		
		Filing Date	March 31, 2004	
		First Named Inventor	Blas Arzubi	
		Art Unit		
		Examiner Name		
Sheet <b>2</b>	of <b>3</b>	Attorney Docket Number	88885	

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
		BARNES, S. The Chemopreventive Properties of Soy Isoflavonoids in Animal Models of Breast Cancer. Breast Cancer Research and Treatment.		
		BARNES, S.; Peterson T.; Coward L. Rationale for the Use of Genistein Containing Soy Matrices in Chemoprevention Trials for Breast and Prostate Cancer. Journal of Cellular Bio		
		PETERSON T.; Barnes S. Genistein and Biochanin A Inhibit the Growth of Human Prostate Cancer Cells but not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation. The P		
		SANTIBANEX J.; Navarro A.; Martinez J. Genistein Inhibits Proliferation and in Vitro Invasive Potential of Human Prostatic Cancer Cell Lines. Anticancer Research 17:1199-1204		
		GELLER J.; Sionit L.; Partido C.; Li L.; Tan X.; Youngkin T.; Nachtsheim D. Genistein Inhibits the Growth of Human-Patient BPH and Prostate Cancer in Histoculture. The Prostat		
		NAIK H.; Lehr J.; Pienta K. An in Vitro and in Vivo Study of Antitumor Effects of Genistein on Hormone Refractory Prostate Cancer. Anticancer Research 14:2617-2620 (1994)		
		LANDSTROM M.; Jie-Xian Zhang; Hallmans G.; Aman P.; Bergh A.; Damber Jan-Erik; Mazur W.; Wahala K.; Adlercreutz H. Inhibitory Effects of Soy and Rye Diets on the Development of		
		POLLARD M.; Luckert P. Influence of Isoflavones in Soy Protein Isolates on Development of Induced Prostate – related Cancers in L-W Rats. Nutrition and cancer. 28(1), 41-45		
		DALU A.; Haskell J.; Coward L.; Lamartiniere C. Genistein, a Component of Soy, Inhibits the Expression of the EGF and ErbB2/Neu Receptors in the Rat Dorsolateral Prostate. The		
		STEPHENS F. Phytoestrogens and Prostate Cancer: possible preventive role. MJA vol.167 Anderson John J.B; Garner Sanford C. The Effects of Phytoestrogens On Bone. Nutrition Res		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:  
**Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	
				Filing Date	March 31, 2004
				First Named Inventor	Arzubi, Blas
				Art Unit	
				Examiner Name	
Sheet	3	of	3	Attorney Docket Number	88885

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		ISHIDA H.; Uesugi T.; Hirai K.; Toda T.; Nukaya H.; Yokotsuka K.; Tsuji K. Preventive Effects of the Plant Isoflavones, Daidzin and Genistin on Bone Loss in Ovariectomized Rats			
		ARJAMANDI B.H.; Alekel, L.; Hollis B.W.; Amin D.; Stacewicz-Sapuntzakis M.; Guo P.; Kukreja S. C. Dietary Soybean Protein Prevents Bone Loss in an Ovariectomized Rat Model of O			
		ERDMAN J.W. Jr, PhD; Potter Susan M., PhD, R.D. Soy and Bone Health. The Soy Connection. Vol 5 No.2 (1997)			
		KOUDY Williams J.; Delansorne Remi; Paris J. Estrogens, Progestins and Coronary Artery reactivity in Atherosclerotic Monkeys. F. Steroid Biochem. Molec. Biol., Vol. 65, no.1-6			
		HONORE E.K.; Koudy Williams J.; Anthony Mary S.; Clarkson T.B. Soy Isoflavones Enhance Coronary Vascular Reactivity in Atherosclerotic Female Macaques. Fertility and Sterility			
		NESTEL P.J.; Yomashita T.; Sasahara T.; Pomeroy Sylvia; Dart A.; Komesaroff P.; Owen Alice; Abbey M. Soy Isoflavones Improve Systemic Arterial Compliance but Not Plasma L			
		DALAIS F.S.; Ricel G.E.; Wahlquist M.L.; Grehan M.; Murkies A.L.; Medley G.; Ayton R.; Strauss B.J.G. Effects of Dietary Phytoestrogens in Postmenopausal Woman. Climacteric 199			
		BRZEZINSKI A.; Adlercreutz H.; Shaoul R.; Rosler A.; Shmueli A.; Tanos V.; Schenker J.G. Short-term Effects of Phytoestrogen-rich Diet on Postmenopausal Woman. Menopause: V			
		ALBERTAZZI P.; Pansini F.; Bonaccorsi G.; Zanotti L.; Forini E.; De Aloysio D. The Effect of Dietary Soy Supplementation and Hot Flushes, Vol.91, No.1, Jan.98			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:  
**Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**